DK3113764T3 - Farmaceutisk sammensætning til transmukosal afgivelse og fremgangsmåder til behandling af diabetes hos et individ, som har behov derfor - Google Patents

Farmaceutisk sammensætning til transmukosal afgivelse og fremgangsmåder til behandling af diabetes hos et individ, som har behov derfor Download PDF

Info

Publication number
DK3113764T3
DK3113764T3 DK15759080.3T DK15759080T DK3113764T3 DK 3113764 T3 DK3113764 T3 DK 3113764T3 DK 15759080 T DK15759080 T DK 15759080T DK 3113764 T3 DK3113764 T3 DK 3113764T3
Authority
DK
Denmark
Prior art keywords
diabetes
individual
needs
treatment
methods
Prior art date
Application number
DK15759080.3T
Other languages
English (en)
Inventor
Joseph Schwarz
Michael Weisspapir
Original Assignee
Eastgate Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eastgate Pharmaceuticals Inc filed Critical Eastgate Pharmaceuticals Inc
Application granted granted Critical
Publication of DK3113764T3 publication Critical patent/DK3113764T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK15759080.3T 2014-03-04 2015-03-04 Farmaceutisk sammensætning til transmukosal afgivelse og fremgangsmåder til behandling af diabetes hos et individ, som har behov derfor DK3113764T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461947698P 2014-03-04 2014-03-04
US201461947678P 2014-03-04 2014-03-04
PCT/IB2015/000390 WO2015132660A1 (en) 2014-03-04 2015-03-04 Pharmaceutical composition for transmucosal delivery and methods for treating diabetes in a subject in need thereof

Publications (1)

Publication Number Publication Date
DK3113764T3 true DK3113764T3 (da) 2020-10-19

Family

ID=54016313

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15759080.3T DK3113764T3 (da) 2014-03-04 2015-03-04 Farmaceutisk sammensætning til transmukosal afgivelse og fremgangsmåder til behandling af diabetes hos et individ, som har behov derfor

Country Status (6)

Country Link
US (1) US10568936B2 (da)
EP (1) EP3113764B1 (da)
CN (1) CN106794146A (da)
CA (1) CA2978517A1 (da)
DK (1) DK3113764T3 (da)
WO (1) WO2015132660A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106794146A (zh) 2014-03-04 2017-05-31 伊斯特盖特医药公司 用于透粘膜递送的药物组合物以及用于在需要的受试者中治疗糖尿病的方法
GB201511284D0 (en) 2015-06-26 2015-08-12 Univ Witwatersrand Jhb An oral pharmaceutical dosage form for the delivery of a peptide and/or protein
CA3038882A1 (en) * 2015-10-14 2017-06-08 Pharcon Inc. Composition for intraoral delivery of biologically active peptides and proteins
CN107773545A (zh) * 2016-08-29 2018-03-09 烟台益诺依生物医药科技有限公司 依达拉奉与(+)‑2‑莰醇的舌下用药物组合物
JP2020508978A (ja) * 2017-02-28 2020-03-26 バイオリンガス アイピー エルエルシー 舌下及びバッカル送達用のオイルベース製剤
WO2018191794A1 (en) 2017-04-20 2018-10-25 Zeenar Enterprises Pty Ltd Liquid crystalline dosage form for administering a statin
EP3664798A4 (en) 2017-08-08 2021-05-05 Kashiv Biosciences, LLC PHARMACEUTICAL COMPOSITION WITH ELIGLUSTAT
MA50414A (fr) 2017-10-19 2020-08-26 Mona E Buice Composition à usage topique pour la cicatrisation améliorée des plaies ouvertes
KR20200132852A (ko) * 2018-01-23 2020-11-25 길라 테라퓨틱스, 인코포레이티드 펩티드 yy 약학적 제형, 조성물, 및 방법
CN112118831B (zh) * 2018-05-17 2023-04-21 费尔廷制药公司 适用于活性药物成分的压片口香糖
WO2020082137A1 (en) * 2018-10-25 2020-04-30 Zeenar Enterprises Pty Ltd Composition that forms liquid crystalline particles
US20220169955A1 (en) * 2019-02-04 2022-06-02 Conopco Inc., D/B/A Unilever Cleaning compositions
WO2020174340A1 (en) * 2019-02-25 2020-09-03 Universidade Nova De Lisboa Eutectic menthol-fatty acid combinations for wound healing
JP2023525019A (ja) * 2020-05-04 2023-06-14 アンファスター・ファーマスーティカルズ・インコーポレイション 薬剤の経鼻送達のための促進剤としての胆汁酸及びその塩の安全な使用
CN112294827B (zh) * 2020-11-12 2021-12-24 四川大学华西医院 5-胆甾烯 -3β-醇硫酸酯盐的用途
CN113209052B (zh) * 2021-03-16 2022-02-15 深圳市泰力生物医药有限公司 大麻二酚自纳米乳口颊膜制剂及其制备方法和用途
US20230058895A1 (en) * 2021-08-06 2023-02-23 Joseph Schwarz Physiologically acceptable eutectic mixtures of cannabidiol

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766620A (en) * 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
WO2000047203A1 (en) 1999-02-12 2000-08-17 Mqs, Inc. Formulation and system for intra-oral delivery of pharmaceutical agents
US6432383B1 (en) * 2000-03-30 2002-08-13 Generex Pharmaceuticals Incorporated Method for administering insulin
US7138394B2 (en) * 2002-09-27 2006-11-21 Alpharx Inc. Vehicle for topical delivery of anti-inflammatory compounds
CN101005828B (zh) * 2004-06-17 2012-01-11 维尔恩公司 用于经粘膜递送活性成分的包含粘膜粘附蛋白和所述活性物质的组合物
IL174387A0 (en) * 2005-03-31 2008-01-20 Dexcel Pharma Technologies Ltd A solid composition for intra-oral delivery of insulin
EP2243490B1 (en) * 2007-12-28 2012-06-13 Shanghai Institute of Pharmaceutical Industry Insulin nasal powder inhalation
WO2010118516A1 (en) * 2009-04-14 2010-10-21 Globe Laboratories Inc. Compositions for sublingual drug delivery and methods of use thereof
EP2958594A4 (en) * 2013-02-22 2017-03-01 Eastgate Pharmaceuticals Inc. Pharmaceutical composition for enhanced transmucosal administration of benzodiazepines
CN106794146A (zh) 2014-03-04 2017-05-31 伊斯特盖特医药公司 用于透粘膜递送的药物组合物以及用于在需要的受试者中治疗糖尿病的方法

Also Published As

Publication number Publication date
US20150250856A1 (en) 2015-09-10
WO2015132660A1 (en) 2015-09-11
US10568936B2 (en) 2020-02-25
CN106794146A (zh) 2017-05-31
EP3113764A1 (en) 2017-01-11
EP3113764A4 (en) 2017-08-30
EP3113764B1 (en) 2020-07-22
CA2978517A1 (en) 2015-09-11

Similar Documents

Publication Publication Date Title
DK3113764T3 (da) Farmaceutisk sammensætning til transmukosal afgivelse og fremgangsmåder til behandling af diabetes hos et individ, som har behov derfor
DK3368108T3 (da) Medikamenttilførselsanordning
DK3722274T3 (da) 2-perfluorbutylpentan til oftalmisk indgivelse
DK3265043T3 (da) Hjælpemiddel til patienttransport og -træning
DK3139986T3 (da) System til administration af terapeutisk gas
DK3145343T3 (da) Aerosolfrembringende substrat og aerosolleveringssystem
DK3236943T3 (da) Sammensætninger til ileo-jejunal lægemiddeladministration
DK3204876T3 (da) Lægemiddelafgivelsesindretning
DK3337539T3 (da) Medikamenttilførselsanordning til variable enkeltdoser
DK2986304T3 (da) Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf.
DK3319611T3 (da) Oxysteroler og fremgangsmåder til anvendelse deraf
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
DK3171921T3 (da) Lægemiddelafgivelsesindretning
DK3319612T3 (da) Oxysteroler og fremgansmåder til anvendelse derfor
DK3928763T3 (da) Transmukosale og transdermale leveringssystemer
DK3094640T3 (da) Fremgangsmåder til steril kromatografi og fremstilling
DK3233111T3 (da) Farmaceutisk sammensætning, der omfatter plasminogen, og anvendelser deraf
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
DK3155017T3 (da) Forbedrede lægemidler til insulinresistens
DK3554534T3 (da) Farmaceutisk sammensætning omfattende insulin
DK3808188T1 (da) Fiskefoder og fremgangsmåde til smoltifikation og forebyggelse af desmoltifikation hos salmonidae samt til profylakse og behandling af hæmoragisk smoltsyndrom (hss) hos salmonidae
DK3223796T3 (da) Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
DK3157522T3 (da) Muskarin-antagonister og kombinationer deraf til behandlingen af luftvejssygdomme i heste
DK3149049T3 (da) Il-22 til anvendelse til behandling af stofskiftesygdomme
DK3353191T3 (da) Cykliske polypeptider, fremgangsmåde til opnåelse deraf og terapeutisk anvendelse deraf